Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review
Targeting therapies; Migraine; Monoclonal antibodies
| Authors: | ; ; ; ; ; |
|---|---|
| Format: | Article |
| Status: | Published version |
| Publication date: | 2024 |
| Country: | España |
| Institution: | Departament de Salut de la Generalitat de Catalunya (DS) |
| Repository: | Scientia. Dipòsit d'Informació Digital del Departament de Salut |
| OAI Identifier: | oai:scientiasalut.gencat.cat:11351/12469 |
| Online Access: | https://hdl.handle.net/11351/12469 |
| Access Level: | Open access |
| Keyword: | Migranya - Tractament Migranya - Prevenció Anticossos monoclonals - Ús terapèutic Neuropèptids DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders Other subheadings::Other subheadings::Other subheadings::/prevention & control CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized Other subheadings::Other subheadings::/therapeutic use CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Neuropeptides::Calcitonin Gene-Related Peptide ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados Otros calificadores::Otros calificadores::/uso terapéutico COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::neuropéptidos::péptido relacionado con el gen de calcitonina |
| _version_ | 1878741413653381121 |
|---|---|
| author | Díaz-Cerezo, Silvia |
| author2 | Fernández-Montoya, Julia de Paz Fernández, Héctor David Núñez, Mercedes Pozo-Rosich, Patricia Garcia Azorin, David |
| author2_role | author author author author author |
| author_browse | Díaz-Cerezo, Silvia Fernández-Montoya, Julia Garcia Azorin, David Núñez, Mercedes Pozo-Rosich, Patricia de Paz Fernández, Héctor David |
| author_facet | Díaz-Cerezo, Silvia Fernández-Montoya, Julia de Paz Fernández, Héctor David Núñez, Mercedes Pozo-Rosich, Patricia Garcia Azorin, David |
| author_role | author |
| collection | Scientia. Dipòsit d'Informació Digital del Departament de Salut |
| description | Targeting therapies; Migraine; Monoclonal antibodies |
| eu_rights_str_mv | openAccess |
| format | article |
| id | ES_e4ba3d4f33befa1e54c19a91d285f56b |
| institution | Departament de Salut de la Generalitat de Catalunya (DS) |
| instname_str | Departament de Salut de la Generalitat de Catalunya (DS) |
| network_acronym_str | ES |
| network_name_str | España |
| oai_identifier_str | oai:scientiasalut.gencat.cat:11351/12469 |
| publishDate | 2024 |
| publishDateSort | 2024 |
| publisher | Frontiers Media |
| publisherStr | Frontiers Media |
| reponame_str | Scientia. Dipòsit d'Informació Digital del Departament de Salut |
| spelling | Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review Díaz-Cerezo, Silvia Fernández-Montoya, Julia de Paz Fernández, Héctor David Núñez, Mercedes Pozo-Rosich, Patricia Garcia Azorin, David Migranya - Tractament Migranya - Prevenció Anticossos monoclonals - Ús terapèutic Neuropèptids DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders Other subheadings::Other subheadings::Other subheadings::/prevention & control CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized Other subheadings::Other subheadings::/therapeutic use CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Neuropeptides::Calcitonin Gene-Related Peptide ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados Otros calificadores::Otros calificadores::/uso terapéutico COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::neuropéptidos::péptido relacionado con el gen de calcitonina Targeting therapies; Migraine; Monoclonal antibodies Teràpies dirigides; Migranya; Anticossos monoclonals Terapias dirigidas; Migraña; Anticuerpos monoclonales Introduction: In the context of migraine preventive therapy, new therapeutic modalities such as monoclonal antibodies targeting the calcitonin gene-related peptide receptor (CGRP) or ligand offer potential advantages over traditional preventive treatments. Methods: This systematic literature review gathered recent real-world evidence from Spain on the use of galcanezumab, a CGRP-targeting treatment, in migraine patients. The review included observational studies in English or Spanish, published from August 2020 to August 2023, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Cochrane guidelines. Results: A total of 29 publications involving 2,592 Spanish adult patients were identified, reporting relevant information on clinical outcomes (treatment effectiveness and safety), treatment persistence and patterns (switching from other therapies and time to discontinuation and restart), and patient-reported outcomes (including satisfaction with treatment). The most frequently reported variables were related to the clinical effectiveness of galcanezumab, demonstrating a significant reduction in monthly migraine days and monthly headache days. Additionally, adverse impact of headache per HIT-6 (Headache Impact Test-6) and disability per MIDAS (Migraine Disability Assessment) also improve. Studies also showed that up to 12-month persistence to galcanezumab ranged from 76.8 to 59.8%. Serious adverse events were rare. None of the publications included health-related quality of life data, either generic or migraine-specific. One study highlighted that galcanezumab treatment would offer high patient satisfaction for people with migraine. Conclusion: The real-world evidence on the use of galcanezumab treatment among the Spanish population shows that its effectiveness, persistence, safety, and impact on health burden align with findings from clinical trials and observational studies conducted in other countries. Future studies should incorporate health-related quality of life data to gain a more holistic understanding of this treatment’s impact. T he author(s) declare that financial support was received for the research, authorship, and/or publication of this article. Eli Lilly sponsored this study and the publication of this article. Frontiers Media https://hdl.handle.net/11351/12469 |
| spellingShingle | Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review Díaz-Cerezo, Silvia Migranya - Tractament Migranya - Prevenció Anticossos monoclonals - Ús terapèutic Neuropèptids DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders Other subheadings::Other subheadings::Other subheadings::/prevention & control CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized Other subheadings::Other subheadings::/therapeutic use CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Neuropeptides::Calcitonin Gene-Related Peptide ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados Otros calificadores::Otros calificadores::/uso terapéutico COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::neuropéptidos::péptido relacionado con el gen de calcitonina |
| status_str | publishedVersion |
| title | Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review |
| title_full | Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review |
| title_fullStr | Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review |
| title_full_unstemmed | Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review |
| title_short | Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review |
| title_sort | Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review |
| topic | Migranya - Tractament Migranya - Prevenció Anticossos monoclonals - Ús terapèutic Neuropèptids DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders Other subheadings::Other subheadings::Other subheadings::/prevention & control CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized Other subheadings::Other subheadings::/therapeutic use CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Neuropeptides::Calcitonin Gene-Related Peptide ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados Otros calificadores::Otros calificadores::/uso terapéutico COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::neuropéptidos::péptido relacionado con el gen de calcitonina |
| topic_facet | Migranya - Tractament Migranya - Prevenció Anticossos monoclonals - Ús terapèutic Neuropèptids DISEASES::Nervous System Diseases::Central Nervous System Diseases::Brain Diseases::Headache Disorders::Headache Disorders, Primary::Migraine Disorders Other subheadings::Other subheadings::Other subheadings::/prevention & control CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal::Antibodies, Monoclonal, Humanized Other subheadings::Other subheadings::/therapeutic use CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Peptides::Neuropeptides::Calcitonin Gene-Related Peptide ENFERMEDADES::enfermedades del sistema nervioso::enfermedades del sistema nervioso central::enfermedades cerebrales::trastornos con cefaleas::cefaleas primarias::trastornos migrañosos Otros calificadores::Otros calificadores::Otros calificadores::/prevención & control COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales::anticuerpos monoclonales humanizados Otros calificadores::Otros calificadores::/uso terapéutico COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::péptidos::neuropéptidos::péptido relacionado con el gen de calcitonina |
| url | https://hdl.handle.net/11351/12469 |